CellCept (Mycophenolate Mofetil)
mycophenolate mofetil (MMF)
Indications
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| Kidney transplant rejection prophylaxis | ≥3 months (with cyclosporine + corticosteroids) | Combination immunosuppression | FDA Approved |
| Heart transplant rejection prophylaxis | ≥3 months (with cyclosporine + corticosteroids) | Combination immunosuppression | FDA Approved |
| Liver transplant rejection prophylaxis | ≥3 months (with cyclosporine + corticosteroids) | Combination immunosuppression | FDA Approved |
Mycophenolate mofetil was first approved in 1995 for kidney transplant rejection prophylaxis and remains one of the most widely prescribed immunosuppressants globally. While the FDA indication is exclusively for organ transplant rejection, mycophenolate mofetil is extensively used off-label in autoimmune conditions, most notably lupus nephritis, where it is considered a first-line agent by all major guidelines (ACR, EULAR, KDIGO). The oral dosage forms should not be used interchangeably with mycophenolic acid delayed-release tablets (Myfortic) without physician supervision as their absorption rates differ.
Lupus nephritis (Class III, IV, V): Standard of care for induction and maintenance; typically 2–3 g/day. Recommended by 2024 ACR LN guideline, 2023 EULAR, and KDIGO 2024 as a backbone of triple therapy regimens. Evidence quality: High (multiple RCTs).
SLE (non-renal, maintenance): Commonly used as a steroid-sparing immunosuppressant for skin, joint, and serosal manifestations. Evidence quality: Moderate.
Autoimmune hepatitis: Used as second-line when azathioprine is not tolerated. Evidence quality: Moderate.
Vasculitis (ANCA-associated, maintenance): Used as alternative to azathioprine for maintenance therapy. Evidence quality: Moderate (IMPROVE trial).
Myasthenia gravis, inflammatory myopathies, pemphigus, IgA nephropathy: Various levels of supporting evidence. Evidence quality: Low to Moderate.
Mycophenolate Mofetil Dosing
FDA-Approved Transplant Dosing (Adults)
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Kidney transplant | 1 g PO/IV BID | 1 g BID | 2 g/day | Begin as soon as possible post-transplant; IV over ≥2 h If GFR <25: do not exceed 1 g BID |
| Heart transplant | 1.5 g PO/IV BID | 1.5 g BID | 3 g/day | Higher dose reflects lower exposure with cyclosporine + corticosteroids IV over ≥2 h; switch to oral ASAP |
| Liver transplant | 1.5 g PO BID or 1 g IV BID | 1.5 g PO BID | 3 g/day oral | IV dose is lower (1 g BID) than oral IV for up to 14 days; switch to oral when tolerated |
Off-Label: Lupus Nephritis Dosing (Adults)
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Lupus nephritis — induction (Class III/IV) | 1 g PO BID | 1–1.5 g PO BID | 3 g/day | Standard backbone per ACR/EULAR/KDIGO guidelines Used with pulse steroids + taper; add voclosporin or belimumab for triple therapy |
| Lupus nephritis — maintenance | 1 g PO BID | 0.5–1.5 g PO BID | 3 g/day | Continue for at least 3–5 years after CRR per 2024 ACR Taper to lowest effective dose guided by clinical response and proteinuria |
| SLE (non-renal, steroid-sparing) | 500 mg PO BID | 1–1.5 g PO BID | 3 g/day | Titrate based on response and tolerability Used alongside hydroxychloroquine; facilitates steroid taper |
Pediatric Dosing (≥3 months)
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Kidney transplant | 600 mg/m² PO BID | 600 mg/m² PO BID | 2 g/day | Use oral suspension for accurate dosing BSA ≥1.25 m²: may use capsules/tablets |
| Heart or liver transplant | 600 mg/m² PO BID | Up to 900 mg/m² PO BID | 3 g/day | Start at 600 mg/m²; increase if tolerated Individualise based on clinical assessment |
Capsules and tablets should not be crushed; the powder is teratogenic and requires careful handling with gloves. Take on an empty stomach for optimal absorption, though stable patients may take with food if needed. The oral suspension (200 mg/mL) can be given via NG tube (minimum 8 French). IV infusion must be given over at least 2 hours — never as bolus (risk of phlebitis and thrombosis). Importantly, CellCept (MMF) and Myfortic (mycophenolic acid delayed-release) are NOT interchangeable without physician supervision because of different absorption profiles.
Pharmacology
Mechanism of Action
Mycophenolate mofetil is a prodrug that undergoes rapid and complete presystemic hydrolysis by esterases to release mycophenolic acid (MPA), the pharmacologically active moiety. MPA is a selective, uncompetitive, and reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH), the rate-limiting enzyme in the de novo pathway of guanosine nucleotide synthesis. Because T and B lymphocytes are critically dependent on the de novo pathway for proliferation (unlike most other cell types, which can utilise the salvage pathway via HGPRT), MPA preferentially targets lymphocyte proliferation while relatively sparing other rapidly dividing cells. This selectivity underpins mycophenolate’s superior tolerability profile compared to older antimetabolites like azathioprine. MPA inhibits both type I and type II IMPDH isoforms, with roughly 5-fold greater potency for type II (the isoform upregulated in activated lymphocytes). Beyond antiproliferative effects, MPA also reduces antibody production, inhibits the glycosylation of adhesion molecules (impairing lymphocyte recruitment to sites of inflammation), and may attenuate smooth muscle proliferation relevant to chronic allograft vasculopathy.
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | Rapid and complete absorption of MMF; presystemic de-esterification to MPA; MPA bioavailability 94% (oral vs IV); Tmax ~1 h with secondary peak at 8–12 h (enterohepatic circulation) | Enterohepatic circulation contributes ~40% of total MPA AUC; drugs disrupting this (cholestyramine, antibiotics) significantly reduce exposure. Food does not affect overall AUC but may reduce Cmax |
| Distribution | MPA Vss = 54 ± 25 L (steady state); MPA protein binding 97% to albumin; MPAG protein binding 82% | In hypoalbuminaemia or renal failure, free MPA fraction increases, potentially increasing efficacy but also toxicity despite unchanged total MPA levels. MPAG can displace MPA from albumin at high concentrations |
| Metabolism | MPA is glucuronidated to MPAG (inactive phenolic glucuronide) primarily by UGT enzymes; pharmacologic activity resides entirely in parent MPA; no CYP involvement for MPA metabolism | Not subject to CYP-mediated drug interactions for its own metabolism; however, the enterohepatic cycle of MPAG creates vulnerability to drugs disrupting gut flora or bile acid recycling |
| Elimination | t½ MPA = 17.9 ± 6.5 h (oral); CL = 193 ± 48 mL/min; 93% recovered in urine (87% as MPAG), 6% in faeces; not removed by hemodialysis at therapeutic concentrations | Twice-daily dosing appropriate; MPAG accumulates 6–8-fold in severe renal impairment (GFR <25). Bile acid sequestrants (cholestyramine) reduce MPA AUC by interrupting enterohepatic recirculation |
Side Effects
Adverse reaction data derive primarily from controlled transplant trials (kidney, heart, liver) using MMF with cyclosporine and corticosteroids. Incidence in autoimmune populations may differ due to lower concomitant immunosuppressive burden but is expected to be qualitatively similar.
| Adverse Effect | Incidence (Kidney 2g/day) | Clinical Note |
|---|---|---|
| Diarrhea | 30.4% | Most common GI effect; dose-related; consider dose reduction or split dosing before switching agents |
| Leukopenia | 28.6% | Expected pharmacologic effect; interrupt or reduce dose if ANC <1.3 × 10³/μL |
| Hypertension | 27.5% | Multifactorial in transplant (CNI contribution); less prominent in autoimmune settings |
| Pain (musculoskeletal) | 24.8% | Includes myalgia, back pain, neck pain |
| Abdominal pain | 22.4% | GI tract is a major target; evaluate for ulceration or perforation if severe |
| Edema (peripheral, facial) | 21.0% | More common in heart/liver transplant; fluid status assessment important |
| Anemia | 20.0% | Monitor CBC; consider PRCA in severe refractory anaemia |
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Congenital malformations (embryofetal toxicity) | ~23–27% malformation rate in exposed pregnancies | First trimester | BOXED WARNING. Avoid in pregnancy. Effective contraception required. External ear, facial (cleft lip/palate), limb, cardiac, renal, and neural tube defects reported |
| Post-transplant lymphoproliferative disorder (PTLD) | 0.4–1.0% (at 2–3 g/day) | Months to years; risk highest in EBV-seronegative patients | Boxed warning; reduce immunosuppression; EBV surveillance in pediatrics |
| Non-melanoma skin cancer | 1.6–4.2% | Months to years | Sun protection (SPF ≥30); regular skin exams; limit UV exposure |
| Fatal infection/sepsis | ~2% kidney/heart; ~5% liver | Any time | Boxed warning; consider dose reduction or discontinuation for new serious infections |
| CMV viremia/syndrome | 13.5% | 1–6 months post-transplant | CMV prophylaxis/preemptive therapy; highest risk in D+/R− serostatus |
| Severe neutropenia (ANC <0.5 × 10³/μL) | Up to 2% (kidney), 2.8% (heart), 3.6% (liver) at 3 g/day | Days 31–180 post-transplant | Interrupt or reduce dose if ANC <1.3 × 10³/μL; perform diagnostic workup; monitor CBC per protocol |
| GI ulceration, hemorrhage, perforation | Uncommon but serious | Any time; use caution with active GI disease | Endoscopic evaluation; intestinal villous atrophy reported; consider dose reduction |
| Progressive multifocal leukoencephalopathy (PML) | Very rare (postmarketing) | Variable | Evaluate any new neurological symptoms; reduce immunosuppression if confirmed |
| Pure red cell aplasia (PRCA) | Rare (postmarketing) | Variable | Consider dose reduction or discontinuation; check parvovirus B19; may be reversible |
| Acute Inflammatory Syndrome (AIS) | Rare (postmarketing) | Weeks to months after initiation or dose increase | Paradoxical pro-inflammatory reaction; discontinue MMF; symptoms typically improve within 24–48 h |
Gastrointestinal effects (diarrhea, nausea, abdominal pain) are the most common reason for dose reduction or discontinuation in clinical practice. Strategies include dividing the total daily dose into 3–4 doses, taking with food (which reduces Cmax but preserves AUC), reducing the dose temporarily, or switching to enteric-coated mycophenolate sodium (Myfortic) under physician supervision. Persistent diarrhea warrants colonoscopy to exclude MMF-associated colitis or villous atrophy, which may mimic coeliac disease histologically.
Drug Interactions
Mycophenolate’s interaction profile is dominated by drugs that alter its enterohepatic circulation, reduce gastrointestinal absorption, or have additive immunosuppressive/myelosuppressive effects. MPA is not metabolised by CYP enzymes, so classic CYP-mediated interactions do not apply to its own metabolism.
Monitoring
- CBC with differentialWeekly ×1 mo, biweekly ×2 mo, then monthly
RoutineCritical for detecting neutropenia (most frequent day 31–180), anemia, and thrombocytopenia. Interrupt or reduce dose if ANC <1.3 × 10³/μL. Severe neutropenia (ANC <0.5 × 10³/μL) in up to 3.6% at 3 g/day. - Pregnancy testingBefore initiation; ongoing as appropriate
RoutineBoxed warning for embryofetal toxicity. Negative pregnancy test required before starting. Two forms of contraception recommended. Counsel on risks at every visit. - Infection surveillanceEvery visit
RoutineBoxed warning for serious infections. Screen for CMV (viremia 13.5%), BK virus (in transplant), herpes, and opportunistic infections. Candida and herpes simplex most common opportunistic infections. - Renal functionBaseline, then periodically
RoutineIn kidney transplant with GFR <25, cap dose at 1 g BID. MPAG accumulates 6–8-fold in severe renal impairment. In lupus nephritis, track proteinuria (UPCR) and eGFR as treatment response markers. - Skin examinationAnnually
RoutineNMSC in 1.6–4.2% of transplant patients. PTLD in 0.4–1.0%. Advise sun avoidance, protective clothing, SPF ≥30. - MPA therapeutic drug monitoringNot routine; consider when indicated
Trigger-basedTarget MPA AUC 30–60 mcg·h/mL in transplant. Consider when switching CNIs, adding/removing interacting drugs, or with unexplained toxicity or rejection/flare despite adequate dosing. - GI symptomsEvery visit
Trigger-basedPersistent diarrhea warrants endoscopy to exclude colitis or villous atrophy. GI bleeding/perforation are uncommon but serious complications.
Contraindications & Cautions
Absolute Contraindications
- Hypersensitivity (including anaphylaxis) to mycophenolate mofetil, mycophenolic acid, or any component.
- Allergy to polysorbate 80 (present in CellCept IV formulation only).
Relative Contraindications (Specialist Input Recommended)
- Pregnancy: Boxed warning — associated with increased first trimester pregnancy loss (45–49%) and congenital malformations (~23–27%). Avoid unless no safer alternative exists. Two forms of contraception required.
- Active serious GI disease: Increased risk of ulceration, hemorrhage, and perforation.
- HGPRT deficiency (Lesch-Nyhan, Kelley-Seegmiller syndromes): May exacerbate disease symptoms due to IMPDH inhibition and uric acid accumulation.
Use with Caution
- Severe renal impairment (GFR <25 in transplant): MPAG accumulates 6–8-fold; do not exceed 1 g BID for kidney transplant.
- Elderly patients (≥65 years): May be at increased risk of CMV disease, GI hemorrhage, and pulmonary edema.
- Concomitant live vaccines: Avoid during treatment; vaccinations may be less effective.
- Blood and semen donation: Avoid during therapy and for 6 weeks (blood) or 90 days (semen) after discontinuation.
Use during pregnancy is associated with increased risks of first trimester pregnancy loss and congenital malformations (external ear, facial, limb, cardiac, renal, nervous system defects). Females of reproductive potential must be counselled regarding pregnancy prevention and planning. Increased risk of lymphoma and other malignancies, particularly of the skin. Increased susceptibility to bacterial, viral (including CMV, BK virus, PML, HBV/HCV reactivation, COVID-19), fungal, and protozoal infections, including opportunistic infections, which may lead to hospitalisation and death.
Patient Counselling
Purpose of Therapy
Mycophenolate mofetil is an immunosuppressant that works by specifically reducing the activity of immune cells (lymphocytes) that can cause organ rejection or drive autoimmune disease. Depending on your condition, it is used either to prevent rejection of a transplanted organ or to control kidney inflammation in lupus. It is always used alongside other medications and requires regular blood monitoring to ensure safety.
How to Take
Take capsules or tablets on an empty stomach, twice daily, approximately 12 hours apart. Do not crush or open capsules — the powder can be harmful, especially during pregnancy. If you miss a dose, take it as soon as you remember unless it is within 2 hours of the next scheduled dose. Avoid grapefruit if you are also taking a calcineurin inhibitor.
Sources
- Genentech, Inc. CELLCEPT (mycophenolate mofetil) prescribing information. Revised May 2025. FDA LabelPrimary source for all transplant dosing, safety data, pharmacokinetics, boxed warnings, and drug interactions in this monograph.
- Appel GB, Contreras G, Dooley MA, et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis (ALMS). J Am Soc Nephrol. 2009;20(5):1103-1112. doi:10.1681/ASN.2008101028Landmark RCT establishing MMF as non-inferior to cyclophosphamide for LN induction (56% vs 53% response at 24 weeks).
- Dooley MA, Jayne D, Ginzler EM, et al. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis (ALMS maintenance). N Engl J Med. 2011;365(20):1886-1895. doi:10.1056/NEJMoa1014460ALMS maintenance phase: MMF was superior to azathioprine for preventing treatment failure (16.4% vs 32.4% at 36 months).
- Sollinger HW. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients (US Renal Transplant Study Group). Transplantation. 1995;60(3):225-232. doi:10.1097/00007890-199508000-00003Original pivotal transplant trial establishing MMF efficacy for kidney allograft rejection prophylaxis.
- Ginzler EM, Dooley MA, Aranow C, et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med. 2005;353(21):2219-2228. doi:10.1056/NEJMoa043731Early NEJM trial showing MMF superiority to IV cyclophosphamide for LN induction (22.5% vs 5.8% complete remission at 24 weeks).
- Sammaritano LR, Askanase A, Bermas BL, et al. 2024 American College of Rheumatology (ACR) guideline for the screening, treatment, and management of lupus nephritis. Arthritis Rheumatol. 2025;77(9):1115-1135. doi:10.1002/art.432122024 ACR LN guideline recommending MMF as backbone of triple therapy with voclosporin or belimumab for Class III/IV LN.
- Fanouriakis A, Kostopoulou M, Andersen J, et al. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis. 2024;83(1):15-29. doi:10.1136/ard-2023-224762EULAR guideline recommending MMF as first-line induction for proliferative LN and supporting add-on belimumab or voclosporin.
- Kidney Disease: Improving Global Outcomes (KDIGO) Lupus Nephritis Work Group. KDIGO 2024 clinical practice guideline for the management of lupus nephritis. Kidney Int. 2024;105(1S):S1-S69. doi:10.1016/j.kint.2023.09.002KDIGO guideline positioning MMF-based triple therapy as preferred initial approach for proliferative LN.
- Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology. 2000;47(2-3):85-118. doi:10.1016/S0162-3109(00)00188-0Comprehensive review of MPA mechanism: selective IMPDH inhibition, lymphocyte-specific antiproliferative effect, and anti-adhesion properties.
- Bullingham RES, Nicholls AJ, Kamm BR. Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet. 1998;34(6):429-455. doi:10.2165/00003088-199834060-00002Definitive PK review: bioavailability 94%, t½ ~17 h, 97% protein binding, enterohepatic cycling contributing ~40% of AUC.
- van Gelder T, Hesselink DA. Mycophenolate revisited. Transpl Int. 2015;28(5):508-515. doi:10.1111/tri.12554Updated clinical pharmacology review covering TDM strategies, drug interactions (cyclosporine vs tacrolimus effect on MPA exposure), and PPI interactions.